Global Antiplatelet Drugs Market Research Report 2020 (Includes Business Impact of COVID-19)

  • TBI12386
  • October 13, 2020
  • Global
  • 106 pages
  • IFF Market Research

"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Antiplatelet Drugs market. Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Antiplatelet Drugs market." Antiplatelet drugs are wrongly referred to as the blood-thinning drugs. They dont thin the blood but instead interfere with the important process by which blood clots. The antiplatelet agent normally decreases the clumping of blood cells thereby decreasing the potentially harmful blood clots. People who are at high risk of heart disease when given antiplatelet agents, their risks of strokes and heart attacks can be avoided. The antiplatelet drug market is expected to propel during the forecast period owing to the increasing organic and inorganic growth taking place within the industry. Moreover, the market for generic is also at a rise thereby giving a boost to the generic antiplatelet drug manufacturers. The amount of money that the companies are spending on research and development is also expected to contribute towards the revenue of the antiplatelet drugs market in the future. For instance, in February 2017, PLx Pharma announced positive antiplatelet data for its Aspertec drug which was published in the Journal of the American College of Cardiology (JACC). Now researchers are concentrating on analyzing the pharmacodynamics and meta-analyses to determine whether one drug has an edge over others. The global Antiplatelet Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. This report focuses on Antiplatelet Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Antiplatelet Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:

  • The Medicines Company
  • AstraZeneca
  • The Medicines Company
  • Portola Pharmaceuticals
  • Bayer Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim Pharmaceuticals
  • Alta Laboratories
  • Shandong Xinhua Pharmaceutical
  • Sanis Health
  • Syntex
  • Hoffmann La Roche
  • Teva
  • Sandoz Canada Incorporated
  • Pharmascience
  • Mylan Pharmaceuticals

Segment by Regions

  • North America
  • Europe
  • China
  • Japan
  • Asia-Pacific

Segment by Type

  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Prasugrel
  • Dipyridamole
  • Ticlopidine
  • Abciximab
  • Tirofiban
  • Others

Segment by Application

  • Hospitals
  • Clinic
  • Emergency Service Centers
  • Ambulatory Surgical Centers
  • Others

In Jan 2020,

Mylan S.A.S. received marketing authorization valid throughout the European Union for Clopidogrel/Acetylsalicylic acid Mylan which is a medicine used to prevent problems caused by blood clots and hardening of the arteries, such as a heart attack, in adults who are already taking both clopidogrel and acetylsalicylic acid as separate tablets. It can be used in the following groups of patients who have a condition known as acute coronary syndrome: patients who have unstable angina (a severe type of chest pain) or who have had a heart attack with no ST-segment elevation (an abnormal reading on an electrocardiogram), including those who are having a stent (a short tube) inserted into an artery to prevent it from closing up; patients being treated for heart attack with ST-segment elevation, when the doctor thinks that they would benefit from thrombolytic treatment (treatment to dissolve blood clots). Clopidogrel/Acetylsalicylic acid Mylan contains two active substances, clopidogrel and acetylsalicylic acid (also known as aspirin) and is a generic medicine. This means that Clopidogrel/Acetylsalicylic acid Mylan contains the same active substance and works in the same way as a reference medicine already authorised in the EU called DuoPlavin.

Table of Contents

Executive Summary
1 Antiplatelet Drugs Market Overview
    1.1 Product Overview and Scope of Antiplatelet Drugs
    1.2 Antiplatelet Drugs Segment by Type
        1.2.1 Global Antiplatelet Drugs Production Growth Rate Comparison by Type (2014-2025)
        1.2.2 Aspirin
        1.2.3 Clopidogrel
        1.2.4 Ticagrelor
        1.2.5 Prasugrel
        1.2.6 Dipyridamole
        1.2.7 Ticlopidine
        1.2.8 Abciximab
        1.2.9 Tirofiban
        1.2.10 Others
    1.3 Antiplatelet Drugs Segment by Application
        1.3.1 Antiplatelet Drugs Consumption Comparison by Application (2014-2025)
        1.3.2 Hospitals
        1.3.3 Clinic
        1.3.4 Emergency Service Centers
        1.3.5 Ambulatory Surgical Centers
        1.3.6 Others
    1.4 Global Antiplatelet Drugs Market by Region
        1.4.1 Global Antiplatelet Drugs Market Size Region
        1.4.2 North America Status and Prospect (2014-2025)
        1.4.3 Europe Status and Prospect (2014-2025)
        1.4.4 China Status and Prospect (2014-2025)
        1.4.5 Japan Status and Prospect (2014-2025)
    1.5 Global Antiplatelet Drugs Market Size
        1.5.1 Global Antiplatelet Drugs Revenue (2014-2025)
        1.5.2 Global Antiplatelet Drugs Production (2014-2025)

2 Global Antiplatelet Drugs Market Competition by Manufacturers
    2.1 Global Antiplatelet Drugs Production Market Share by Manufacturers (2014-2019)
    2.2 Global Antiplatelet Drugs Revenue Share by Manufacturers (2014-2019)
    2.3 Global Antiplatelet Drugs Average Price by Manufacturers (2014-2019)
    2.4 Manufacturers Antiplatelet Drugs Production Sites, Area Served, Product Types
    2.5 Antiplatelet Drugs Market Competitive Situation and Trends
        2.5.1 Antiplatelet Drugs Market Concentration Rate
        2.5.2 Antiplatelet Drugs Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global Antiplatelet Drugs Production Market Share by Regions
    3.1 Global Antiplatelet Drugs Production Market Share by Regions
    3.2 Global Antiplatelet ...
| 

Request a sample

Fill below form to request a sample


Please fill this form to enquire before buying


You can request for discount regarding the report by using below form